NIDA research grant · Biotech
Delix Therapeutics awarded $320,000 NIDA grant for DLX-007
The December 2023 award supports research into a neuroplastogen for substance-use disorders.
Delix Therapeutics announced a $320,000 grant from the National Institute on Drug Abuse on December 13, 2023. NIDA is part of the U.S. National Institutes of Health.
The award supports further development of DLX-007, a neuroplastogen being studied for substance-use disorders. The work builds on the company’s collaboration with NIDA’s Addiction Treatment Discovery Program, which evaluates potential treatments through preclinical screening.
Use of funds
Advance DLX-007 research for substance-use disorders